Hims & Hers plummets 16% after first-quarter loss, weak guidance

Piotr Swat | Light Rocket | Getty Images
telehealth company His and Hers Shares fell in early trading Tuesday following a first-quarter loss and weak earnings expectations for next year.
Digital health firm reports net loss of $92 million first quarter profit As of Monday, it was roughly $50 million compared to the same period the previous year. Its adjusted EBITDA fell to $44 million from $91 million last year. Meanwhile, revenue rose 4% to $608 million. Average monthly revenue per subscriber fell to $80 from $85 last year.
Hims expects revenue between $680 million and $700 million for the second quarter and forecasts revenue of up to $3 billion for the full year.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) are estimated to reach $55 million for the second quarter and up to $350 million for the full year.
The company’s shares were last trading down 15.7% in premarket trading.
Hims & Hers has been splitting its shares year-to-date.
Citi analysts called forecasts “mixed” and noted that Hims & Hers’ second-quarter outlook fell short of Citi’s estimates.
Analysts also noted that the first quarter marked a “transitional” phase for the company as it reduced reliance on compound GLP-1s.
An agreement was reached with Hims Novo Nordisk In March, it will sell the GLP-1 weight loss drug Wegovy on its platform and has also committed to stop advertising cheaper knockoff versions of the drug, known as compounded drugs.
Hims’ shares often react sharply to any news that could impact its ability to sell weight-loss drugs to consumers, a highly profitable business for the telehealth company.



